Oasmia Pharmaceutical AB (STO:OASM), a developer of a new generation of drugs within human and veterinary oncology, announced on Wednesday the appointment of Anette Sjödin as EVP, effective 1 June 2019.

In her new role as EVP, Sjödin will focus on commercialisation and business development. Sjödin will be part of the company's management team.

Sjödin, who has over 25 years of experience in the Life Science sector and is a biochemist with many years of global experience, most recently was in business development at Nestlé Skin Health, where she has worked internationally with in- and out licensing and was responsible for strategic alliances.

Maria Nilsson Hagberg has been appointed as head of Regulatory Affairs, as of 18 April 2019.

Hagberg, a pharmacist with over 15 years of experience as a regulatory affairs specialist, has held a number or leadership roles, including as CEO and head of Regulatory Affairs for a regulatory consulting company as well as regulatory affairs manager at Fresenius Kabi on an international level.